Ranitidine was first developed in 1981 in Europe by Glaxo Holdings Ltd, now part of GlaxoSmithKline (GSK) PLC. It got its first American approval in 1983, along with 31 other countries. It was ...

At present, there is no proposal to prohibit the manufacture, distribution and sale of Ranitidine, a medication used to reduce stomach acid, in the country, Minister of State for Health Anupriya ...

New Delhi: There is no plan to ban the manufacture and sale of ranitidine despite concerns over N-nitrosodimethylamine (NDMA), an impurity in the drug which has been found to degrade into a probable ...

Figure 4. Novel mechanisms regulating CAG development. Recent studies have found that other novel mechanisms are associated with the regulation of CAG development, including angiogenesis, energy ...

Zantac’s Developer Settles Lawsuits Claiming Cancer Link GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making ...

Zantac not a cause of woman’s cancer, jury says in first trial over drug By Diana Novak Jones May 23, 202411:47 AM PDTUpdated May 23, 2024 ...

Zantac pharma exec calls heartburn drug safe and effective during testimony against cancer claims The executive, a medical doctor who oversaw drug safety for decades at drugmaker GSK, repeatedly ...

And in 2022, in a lawsuit brought by other plaintiffs in another Zantac case, a U.S. federal court judge ruled “the plaintiffs had no reliable evidence.” Sanofi acquired Zantac in 2017.